卵巢癌因其高度侵袭性而成为妇科癌症死亡的主要原因。免疫疗法已成为卵巢癌治疗的一种有前途的途径，提供了减少脱靶效应的有针对性的方法。随着下一代测序的出现，识别基因组改变已成为可能，这些改变可以作为免疫治疗的潜在靶点。此外，免疫基因组学研究揭示了遗传改变在塑造癌症免疫反应中的重要性。然而，免疫原性的异质性和低肿瘤突变负担给基于新抗原的免疫疗法带来了挑战。需要进一步研究来识别新抗原特异性肿瘤浸润淋巴细胞 (TIL)，并为基于 TIL 的治疗中的患者纳入标准制定指南。新抗原及其在卵巢癌免疫治疗中的影响的研究前景广阔，专注于个性化治疗策略、精细新抗原选择和优化治疗组合的努力将有助于改善未来患者的治疗结果。版权所有 © 2023。由 Elsevier B.V. 出版。

Ovarian cancer is a major cause of death among gynecological cancers due to its highly aggressive nature. Immunotherapy has emerged as a promising avenue for ovarian cancer treatment, offering targeted approaches with reduced off-target effects. With the advent of next-generation sequencing, it has become possible to identify genomic alterations that can serve as potential targets for immunotherapy. Furthermore, immunogenomics research has revealed the importance of genetic alterations in shaping the cancer immune responses. However, the heterogeneity of immunogenicity and the low tumor mutation burden pose challenges for neoantigen-based immunotherapies. Further research is needed to identify neoantigen-specific tumor-infiltrating lymphocytes (TIL) and establish guidelines for patient inclusion criteria in TIL-based therapy. The study of neoantigens and their implications in ovarian cancer immunotherapy holds great promise, and efforts focused on personalized treatment strategies, refined neoantigen selection, and optimized therapeutic combinations will contribute to improving patient outcomes in the future.Copyright © 2023. Published by Elsevier B.V.